| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,740,000 |
| Market
Cap: |
32.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.98 - $2.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients with rare infectious diseases. Co.'s initial product candidate, epetraborole, an antibiotic under development as a once-daily, oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
18,610 |
18,610 |
1,880,610 |
3,658,388 |
| Total Buy Value |
$20,798 |
$20,798 |
$2,014,166 |
$18,014,168 |
| Total People Bought |
2 |
2 |
5 |
6 |
| Total Buy Transactions |
2 |
2 |
13 |
14 |
| Total Shares Sold |
2,732,000 |
2,749,606 |
6,274,700 |
6,840,331 |
| Total Sell Value |
$3,090,477 |
$3,114,086 |
$6,921,188 |
$17,154,863 |
| Total People Sold |
1 |
5 |
6 |
12 |
| Total Sell Transactions |
3 |
7 |
8 |
44 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Easom Eric |
Chief Executive Officer |
• • – |
2025-06-02 |
4 |
B |
$1.07 |
$10,665 |
D/D |
10,000 |
256,380 |
0.01 |
2% |
|
| Leonard Braden Michael |
|
• • • |
2025-05-30 |
4 |
S |
$1.01 |
$436,477 |
I/I |
(432,000) |
3,217,432 |
|
-2% |
|
| Leonard Braden Michael |
|
• • • |
2025-05-28 |
4 |
S |
$1.09 |
$218,000 |
I/I |
(200,000) |
3,017,432 |
|
6% |
|
| Leonard Braden Michael |
|
• • • |
2025-05-28 |
4 |
S |
$1.16 |
$2,436,000 |
I/I |
(2,100,000) |
3,649,432 |
|
6% |
|
| Fitzpatrick Margaret M |
|
– • – |
2025-05-28 |
4 |
B |
$1.18 |
$10,133 |
D/D |
8,610 |
8,610 |
0.01 |
-6% |
|
| Zakrzewski Joseph S |
|
– • – |
2025-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
10,523 |
145,538 |
|
- |
|
| Marks Gilbert Lynn |
|
– • – |
2025-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,705 |
41,507 |
|
- |
|
| Martin Patricia A. |
|
– • – |
2025-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
3,065 |
6,231 |
|
- |
|
| Aziz Kabeer |
|
– • – |
2025-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,705 |
18,677 |
|
- |
|
| Eizen Joshua M |
See Remarks |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
58,500 |
175,172 |
|
- |
|
| Chanda Sanjay |
Chief Development Officer |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
50,250 |
80,074 |
|
- |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
145,250 |
246,380 |
|
- |
|
| Day Lucy |
Chief Financial Officer |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
46,500 |
79,170 |
|
- |
|
| Prior Stephen David |
Chief Strategy Officer |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
61,313 |
|
- |
|
| Chanda Sanjay |
Chief Development Officer |
• – – |
2025-01-03 |
4 |
S |
$1.34 |
$3,965 |
D/D |
(2,957) |
29,824 |
|
13% |
|
| Day Lucy |
Chief Financial Officer |
• – – |
2025-01-03 |
4 |
S |
$1.34 |
$3,965 |
D/D |
(2,957) |
32,670 |
|
13% |
|
| Prior Stephen David |
Chief Strategy Officer |
• – – |
2025-01-03 |
4 |
S |
$1.34 |
$2,721 |
D/D |
(2,029) |
33,313 |
|
13% |
|
| Eizen Joshua M |
See Remarks |
• – – |
2025-01-03 |
4 |
S |
$1.34 |
$12,958 |
D/D |
(9,663) |
116,672 |
|
13% |
|
| Marks Gilbert Lynn |
|
– • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,972 |
31,802 |
|
- |
|
| Aziz Kabeer |
|
– • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,972 |
8,972 |
|
- |
|
| Readnour Robin Shane |
|
– • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
9,077 |
9,077 |
|
- |
|
| Zakrzewski Joseph S |
|
– • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
9,816 |
135,015 |
|
- |
|
| Martin Patricia A. |
|
– • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,166 |
3,166 |
|
- |
|
| Readnour Robin Shane |
|
– • – |
2024-12-10 |
4 |
B |
$1.49 |
$14,930 |
I/I |
10,000 |
652,573 |
0.01 |
-16% |
|
| Readnour Robin Shane |
|
– • – |
2024-12-09 |
4 |
B |
$1.43 |
$43,984 |
I/I |
30,772 |
647,573 |
0.01 |
-7% |
|
127 Records found
|
|
Page 1 of 6 |
|
|
